MVision AI, founded in 2017 and based in Helsinki, Finland, is a pioneering, cloud-based software service provider for radiotherapy treatment planning. The company’s unique, AI-powered automatic segmentation tool helps to standardize contouring and automate segmentation to streamline radiotherapy treatment planning. The next-generation technology speeds up the entire cancer treatment process, reducing treatment waiting times significantly from weeks to days.
The technology has already been used to treat more than 100,000 cancer patients in 14 countries, with most patients from Finland, Sweden and the UK. The scalable platform enables the improvement of cancer treatments worldwide.
Now, the Finnish startup raises EUR 5.4 million in Post Seed financing to further accelerate cancer treatment automation and to bring the solution to more patients. The funding round was led by Swedish J12 Ventures and Finnish Voima Ventures.
We are making same-day treatment a standard in cancer treatment globally.
“The burden of cancer is growing for patients, hospitals, and carers. Our cloud-based AI-powered technology provides faster and more reliable clinical decision-making for cancer patients undergoing radiotherapy treatment. With our automation, we can speed up the entire treatment planning process while still delivering high-quality care,” MVision’s founder and CEO Mahmudul Hasan says.
With manual treatment planning, a patient diagnosed with cancer often needs to wait 2–3 weeks for treatment to start.
“Our automation enables same-day treatment. We are making same-day treatment a standard in cancer treatment globally,” Hasan adds.
MVision’s platform has already helped reduce wait-time significantly in several cancer clinics worldwide. MVision AI is the first cloud-based AI-powered radiotherapy planning solution for treating cancer.